October 5, 2016 / 6:06 AM / a year ago

Swiss stocks - Factors to watch on Oct 5

ZURICH, Oct 5 (Reuters) - The Swiss blue-chip SMI was seen opening 0.3 percent down at 8,208 points on Wednesday, according to premarket indications by bank Julius Baer .

The following are some of the main factors expected to affect Swiss stocks.


The U.S. Food and Drug Administration has granted Roche breakthrough status to its anti-rheumatoid arthritis medication Actemra/RoActemra (tocilizumab) for giant cell arteritis (GCA). Giant cell arteritis is a chronic, potentially life-threatening autoimmune condition caused by inflammation of large and medium-sized arteries, most often in the head, but also in the aorta and its branches.

For more click on


* Daetwyler said on Tuesday it is investing more than 100 million Swiss francs ($102.04 million) in a new U.S. plant in Delaware manufacture elastomer components for injectable drug delivery systems. ($1 = 0.9800 Swiss francs) (Reporting by Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below